| [1] |
Mi XK, Liu QR, Zhu L, et al. Mechanism of the high coagulation state of breast cancer tissue factor[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9):2167-2171.
|
| [2] |
Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer[J]. J Am Coll Cardiol, 2017, 70(19): 2411-2420.
|
| [3] |
Yamashita Y, Wada H, Nomura H, et al. Elevated fibrin-related markers in patients with malignant diseases frequently associated with disseminated intravascular coagulation and venous thromboembolism[J]. Intern Med, 2014, 53(5):413-419.
|
| [4] |
Soomro AY, Guerchicoff A, Nichols DJ, et al. The current role and future prospects of D-dimer biomarker[J]. Eur Heart J Cardiovasc Pharmacother, 2016, 2(3): 175-184.
|
| [5] |
Babak T, Padideh O, Morteza AE. The prediction role of D-dimer in recurrence of venous thromboembolism 1-year after anticoagulation discontinuing following idiopathic deep vein thrombosis [J]. J Res Med Sci, 2014, 19(7): 586-591.
|
| [6] |
Tinholt M, Sandset PM, Mowinckel MC, et al. Determinants of acquired activated protein C resistance and D-dimer in breast cancer[J]. Thromb Res, 2016, 145:78-83.
|
| [7] |
Chaari M, Ayadi I, Rousseau A, et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability[J]. BMC Cancer, 2014, 14: 991.
|
| [8] |
Gao XL, Wang SS, Cao DB, et al. The role of D-dimer testing in clinical hematology and oncology[J]. Clin Respir J, 2018, 12(6): 2151-2156.
|
| [9] |
Rubio-Jurado B, Balderas-Peña LM, García-Luna EE, et al. Obesity, thrombotic risk, and inflammation in cancer[J]. Adv Clin Chem, 2018, 85:71-89.
|
| [10] |
Tas F, Kilic L, Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer[J]. Tumour Biol, 2014, 35(6): 5985-5992.
|
| [11] |
Li W, Tang Y, Song Y, et al. Prognostic role of pretreatment plasma D-dimer in patients with solid tumors: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018, 45(4): 1663-1676.
|
| [12] |
S H, Sringeri RR, Chandra PS. Role of plasma D-dimer levels in breast cancer patients and its correlation with clinical and histopathological stage[J]. Indian J Surg Oncol, 2018, 9(3): 307-311.
|
| [13] |
Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay[J]. Nat Biotechnol, 2013, 31(6): 539-544.
|
| [14] |
Mego M, Karaba M, Minarik G, et al. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients[J]. Breast J, 2015, 21(2): 155-160.
|
| [15] |
Khoury JD, Adcock DM, Chan F, et al. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer[J]. Am J Clin Pathol, 2010, 134(6): 964-969.
|
| [16] |
Mego M, Zuo Z, Gao H, et al. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer[J]. Thromb Haemost, 2015, 113(3): 593-598.
|
| [17] |
吴杰，徐笑红，包叶江，等. 乳腺癌中血浆D-二聚体水平的变化及其与临床病理关系的研究[J]. 浙江医学，2013，35(14):1336-1338.
|
| [18] |
Arora M, Wun T. Adverse impact of venous thromboembolism on patients with cancer[J]. Semin Thromb Hemost, 2014, 40(3): 313-318.
|
| [19] |
Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients[J]. Haematologica, 2012, 97(8): 1158-1164.
|
| [20] |
Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression[J]. Thromb Res, 2018, 164 Suppl 1: S54-S61.
|
| [21] |
Kirwan CC, McCollum CN, McDowell G, et al. Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis[J]. Clin Appl Thromb Hemost, 2015, 21(5): 420-427.
|
| [22] |
Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation[J]. J Clin Oncol, 2009, 27(17): 2758-2765.
|
| [23] |
Pallis AG, Hatse S, Brouwers B, et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging？[J]. J Geriatr Oncol, 2014, 5(2): 204-218.
|
| [24] |
Yuan Y, Vora N, Sun CL, et al. Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with physical function in women with breast cancer[J]. Oncologist, 2017, 22(10): 1189-1196.
|
| [25] |
Yuan JQ, Wang SM, Tang LL, et al. Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2015, 151(2): 405-413.
|
| [26] |
Sandy J, Della-Fiorentina S. Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic[J]. Asia Pac J Clin Oncol, 2013, 9(4): 365-372.
|
| [27] |
Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research[J]. J Clin Oncol, 2014, 32(24): 2611-2616.
|
| [28] |
Peterson MJ, Thompson DK, Pieper CF, et al. A novel analytic technique to measure associations between circulating biomarkers and physical performance across the adult life span[J]. J Gerontol A Biol Sci Med Sci, 2016, 71(2): 196-202.
|
| [29] |
Yuan Y, Vora N, Sun CL, et al. Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer[J]. Breast Cancer Res, 2017, 19(1): 101.
|
| [30] |
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices[J]. J Clin Oncol, 2003, 21(24): 4524-4531.
|
| [31] |
Wang Z, Dang C, Zhu K, et al. Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients[J]. Mol Clin Oncol, 2015, 3(5): 1088-1092.
|
| [32] |
D’Alessio A, Marchetti M, Tartari CJ, et al. Long term low molecular weight heparin anticoagulant therapy modulates thrombin generation and D-dimer in patients with cancer and venous thromboembolism[J]. Cancer Invest, 2017, 35(7): 490-499.
|
| [33] |
Walker AJ, West J, Card TR, et al. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data[J]. Blood, 2016, 127(7): 849-857.
|
| [34] |
Rousseau A, Larsen AK, Van Dreden P, et al. Differential contribution of tissue factor and factor Ⅻ to thrombin generation triggered by breast and pancreatic cancer cells[J]. Int J Oncol, 2017, 51(6): 1747-1756.
|
| [35] |
Kim Y, Kim OJ, Kim J. Cerebral venous thrombosis in a breast cancer patient taking tamoxifen: report of a case[J]. Int J Surg Case Rep, 2015, 6C: 77-80.
|